TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35337339
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of famitinib, camrelizumab, and chemotherapy
Study: 35337388
Drug: Multimodal physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal physical therapy program (manual therapy, therapeutic exercise, static progressive splinting) over 4 weeks
Study: 35337388
Drug: Manipulation under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manipulation under anesthesia followed by physical therapy
Study: 35337972
Drug: Abemaciclib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib + Endocrine Therapy (ET)
Study: 35384873
Drug: Endocrine Therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine Therapy (ET) alone
Study: 35338252
Drug: Average total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average total fluid administration (TFA) > 150 mL/kg birthweight/day
Study: 35338773
Drug: CD19-specific CAR
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19-specific CAR T cell-based therapy
Study: 35340685
Drug: nCRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCRT with a total dose of 55 Gy in 25 fractions on Gross Tumor Volume (GTV) plus 45 Gy in 25 fractions on the whole pelvis, with continuous oral capecitabine chemotherapy.
Study: 35341327
Drug: Evidence-based treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based treatments
Study: 35341613
Drug: Medication for
Normalized name: SALICYLIC ACID 10 mg in 1 mL TOPICAL LOTION [Serious Skincare Continuously Clear Acne Medication For Problematic skin Dry Lo Pro All- Over Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication for addiction treatment (MAT)
Study: 35341724
Drug: Radial wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radial wave therapy (RW group) - 6 weekly sessions
Study: 35341724
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (control group) - 6 weekly sessions
Study: 35341724
Drug: Radial wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radial wave therapy (RW group)
Study: 35341952
Drug: Rectal expulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal expulsion device (RED)
Study: 35342321
Drug: E-GPS (Glasgow
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-GPS (Glasgow prognostic score after first-line chemotherapy)
Study: 35342822
Drug: ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranibizumab (0.5 or 2.0 mg) monthly or as-needed (PRN) for 24 months
Study: 35343187
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg for six cycles or until disease progression or unacceptable toxicity or withdrawal
Study: 35343910
Drug: PEAR-004, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEAR-004, a smartphone-based investigational digital therapeutic, added to standard treatments for schizophrenia.
Study: 35344040
Drug: Venetoclax as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax as a monotherapy
Study: 35345248
Drug: DAPT (dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT (dual antiplatelet therapy)
Study: 35345248
Drug: PCI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCI treatment
Study: 35346070
Drug: Selective internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective internal radiation therapy (SIRT) with yttrium-90, target mean dose to tumor is ≥ 150 Gy.
Study: 35346070
Drug: Selective internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective internal radiation therapy (SIRT) with yttrium-90
Study: 35346165
Drug: Moderate albuminuria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate albuminuria (UACR 30-300 mg/g)
Study: 35346165
Drug: Severe albuminuria
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe albuminuria (UACR > 300 mg/g)
Study: 35346219
Drug: Opioid Medication
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid Medication Therapy (OMT)
Study: 35347559
Drug: Glesatinib 700
Normalized name: Glesatinib
DrugBank: Glesatinib (DB06302)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glesatinib 700 mg twice daily (micronized V2) with erlotinib 150 mg once daily
Study: 35347559
Drug: Glesatinib 700
Normalized name: Glesatinib
DrugBank: Glesatinib (DB06302)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glesatinib 700 mg twice daily (micronized V2) with docetaxel 75 mg/m2
Study: 35347559
Drug: Glesatinib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glesatinib (various formulations) plus erlotinib or docetaxel
Study: 35348754
Drug: Apatinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (500 mg orally daily)
Study: 35349331
Drug: Sorafenib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (200 mg/m) added to conventional AML chemotherapy
Study: 35349331
Drug: Conventional AML
Normalized name: AML-2-23
DrugBank: AML-2-23 (DB17433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional AML chemotherapy
Study: 35349491
Drug: CIML NK
Normalized name: IL15-NK Cell
DrugBank: IL15-NK Cell (DB15725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIML NK cells infused after lymphodepleting chemotherapy (5 to 10 million cells/kg) followed by systemic IL-2 for 7 doses.
Study: 35349683
Drug: Marine oil
Normalized name: marine non-gelling gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine oil supplement (2 g/d for 28-30 days)
Study: 35350834
Drug: First dose
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First dose of the COVID-19 vaccine
Study: 35350834
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of the COVID-19 vaccine
Study: 35350834
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of the COVID-19 vaccine
Study: 35351181
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of p-tau217 with hippocampal volume, cognition, and APOE genotype
Study: 35351181
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of p-tau217 and cognition
Study: 35351214
Drug: Restrictive intravenous
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive intravenous fluid protocol
Study: 35352097
Drug: Electronic dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic dose monitoring (EDM) for ART adherence
Study: 35352102
Drug: Daily coformulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily coformulated tenofovir disoproxil fumarate and emtricitabine for HIV prevention
Study: 35352313
Drug: Guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 100 mg every 4 or 8 weeks
Study: 35352512
Drug: sintilimab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: sintilimab (200 mg IV every 2 weeks for three cycles) plus hypofractionated radiotherapy (5 Gy × 5)
Study: 35352766
Drug: Albuterol and
Normalized name: Albuterol and cromolyn only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol and ipratropium bromide delivered via pressurized metered-dose inhaler with holding chamber and systemic corticosteroids
Study: 35353154
Drug: Dual pathway
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual pathway inhibition (DPI) with a P2Y12 inhibitor (clopidogrel or ticagrelor) and a vascular dose of rivaroxaban
Study: 35353154
Drug: DAPT with
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT with a P2Y12 inhibitor (clopidogrel or ticagrelor)
Study: 35353219
Drug: IDH305 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDH305 at doses 75-750 mg twice daily
Study: 35353263
Drug: Drug switching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug switching
Study: 35353263
Drug: MASES and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MASES and BASMI scores in drug switchers
Study: 35353962
Drug: Primaquine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine at a total dose of 7.0 mg per kilogram
Study: 35354274
Drug: Avelumab, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab, dosage not specified, duration not specified
Study: 35354808
Drug: Devimistat in
Normalized name: Devimistat
DrugBank: Devimistat (DB12109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Devimistat in combination with high dose cytarabine and mitoxantrone
Study: 35355447
Drug: Daprodustat (6-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daprodustat (6-mg single dose)
Study: 35355714
Drug: Psilocybin (medium-high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (medium-high doses)
Study: 35355991
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of melatonin and DADA (diisopropylamine dichloroacetate)
Study: 35355991
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of melatonin and DADA
Study: 35356197
Drug: CD19-CAR T
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19-CAR T cell therapy (tisagenlecleucel or on an institutional clinical trial)
Study: 35356225
Drug: Conventional surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional surgical treatment group (Group B)
Study: 35356262
Drug: Pyrotinib-based therapy
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib-based therapy
Study: 35357027
Drug: Dostarlimab (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dostarlimab (1, 3 or 10 mg/kg)
Study: 35357325
Drug: Mindfulness mobile
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness mobile application (Headspace) used daily for 30 days (up to 10 minutes a day)
Study: 35358443
Drug: Index therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Index therapies included immunochemotherapy (n=133)
Study: 35358443
Drug: Index therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Index therapies included anti-CD20 antibody monotherapy (n=53)
Study: 35358443
Drug: Index therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Index therapies included lenalidomide with or without anti-CD20 (n=37)
Study: 35358443
Drug: Index therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Index therapies included phosphoinositide 3-kinase inhibitors with or without anti-CD20 (n=25)
Study: 35358810
Drug: Baseline phenotypic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline phenotypic measurements (e.g., patient global estimate of health status, 6-min walk distance, HRQoL measures)
Study: 35359000
Drug: Atezolizumab (atezo)
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab (atezo) with obinutuzumab (G) and bendamustine
Study: 35359899
Drug: Investigational Medicinal
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Investigational Medicinal Product (IMP) - Molecular radiotherapy (details on dosage and duration not available)
Study: 35360218
Drug: ICP-directed treatment
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-directed treatment
Study: 35360224
Drug: Autonomic Regulation
Normalized name: AUTONOMIC MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autonomic Regulation Therapy (ART) using chronic vagus nerve stimulation (VNS)
Study: 35361185
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy aimed at stabilizing the hip joint
Study: 35361185
Drug: Arthroscopic plication
Normalized name: MANGANESE DICATION
DrugBank: Manganese cation (DB06757)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic plication of the hip joint capsule
Study: 35361487
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg administered intravenously Q3W for up to 35 cycles (approximately 2 years)
Study: 35361691
Drug: Third SARS-CoV-2
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third SARS-CoV-2 vaccine
Study: 35362857
Drug: Steroid use
Normalized name: Antiinflammatory preparations, non-steroids for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid use in the second wave
Study: 35362862
Drug: Low-dose estrogen/progestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose estrogen/progestin (LEP)
Study: 35362862
Drug: Non-LEP treatment
Normalized name: rabies virus vaccine flury-lep strain Injection [RabAvert]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-LEP treatment (NSAIDs or Chinese herbal medicines)
Study: 35362878
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (4 capsules of 530 mg EPA, 150 mg DHA)
Study: 35363252
Drug: GIP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIP infusion after bariatric surgery
Study: 35364421
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks for ≤35 cycles
Study: 35364569
Drug: LCTOPC1 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCTOPC1 (2 × 10^6 cells) administered via intraparenchymal injection
Study: 35366263
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nutraceuticals for 6 months as part of a Mediterranean diet
Study: 35366312
Drug: Iron deficiency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron deficiency treatment
Study: 35366312
Drug: Vitamin deficiency
Normalized name: Vitamin Deficiency Injectable System - B12 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin deficiency treatment
Study: 35366613
Drug: Standard 'next-step'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 'next-step' treatment strategies
Study: 35366711
Drug: Elevated blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated blood hemoglobin (HGB > 149.5 g/L)
Study: 35366711
Drug: Normal blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal blood hemoglobin (HGB ≤ 149.5 g/L)
Study: 35366805
Drug: Antiviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral treatment for HBV (20.3% of patients received this treatment)
Study: 35366825
Drug: Preoperative accelerated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative accelerated partial breast irradiation (APBI) using CyberKnife, single fraction (exact dosage not specified)
Study: 35366963
Drug: Odronextamab (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odronextamab (up to 320 mg once per week, with maintenance every 2 weeks after cycle 4)
Study: 35366963
Drug: Odronextamab (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odronextamab (doses of 5 mg or higher)
Study: 35366963
Drug: Odronextamab (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odronextamab (doses of 80 mg or higher)
Study: 35367396
Drug: iNKT cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: iNKT cell and PD-1+CD8+ T cell-based immunotherapy, infused every 3-5 weeks, considered 1 cycle.
Study: 35367396
Drug: iNKT cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: iNKT cell and PD-1+CD8+ T cell-based immunotherapy
Study: 35367616
Drug: Fluorescence guided
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorescence guided photodynamic therapy (PDT) using a portable fibre-coupled LED system
Study: 35367616
Drug: Fluorescence guided
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorescence guided photodynamic therapy (PDT)
Study: 35367851
Drug: Automatic dose
Normalized name: AMMONIA,AROMATIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic dose verification system with propagated contours
Study: 35367908
Drug: Cancer screening,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer screening, risk reduction, and treatment
Study: 35368221
Drug: 1.5% ruxolitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% ruxolitinib cream applied twice daily for 28 days, then continued on active lesions for an additional 28 days (extension period).
Study: 39546129
Drug: 1.5% ruxolitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% ruxolitinib cream
Study: 35369018
Drug: p-inulin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: p-inulin (8 g twice daily for 12 weeks)
Study: 35369018
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (pretreatment phase)
Study: 35369374
Drug: Medications containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications containing acid salts (Metformin hydrochloride at 2550 mg/d and Gabapentin hydrochloride at 2700 mg/d)
Study: 35369374
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride (15.4 meq/d)
Study: 35369607
Drug: Ramucirumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (10 mg/kg) plus Gefitinib (250 mg/d)
Study: 35369854
Drug: Inactivated SARS-CoV-2
Normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated SARS-CoV-2 vaccines
Study: 35371427
Drug: Hetrombopag (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hetrombopag (7.5 mg once daily to a maximum of 15 mg once daily for 52 weeks)
Study: 35373040
Drug: Lawton Instrumental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lawton Instrumental Activities of Daily Living (IADL)
Study: 35373105
Drug: COVID-19 mRNA
Normalized name: COVID-19 mRNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 mRNA vaccines (BNT162b2 [BioNTech/Pfizer] or mRNA-1273 [Moderna])
Study: 35373299
Drug: ADXS31-142 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADXS31-142 monotherapy (n = 13)
Study: 35377133
Drug: Piperacillin-tazobactam 12/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam 12/1.5 g/24 h as a continuous infusion
Study: 35377133
Drug: Regular dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dose of 12/1.5 g/24 h
Study: 35377133
Drug: Dosing guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing guided by renal function and therapeutic drug monitoring
Study: 35378750
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Summer Camp and Parent Intervention (SCV + PI)
Study: 35378952
Drug: Hydroxychloroquine 400
Normalized name: hydroxychloroquine 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 400 mg BID on the first day, then 400 mg OD for a total of seven days
Study: 35379237
Drug: Selinexor 80
Normalized name: SELINEXOR 80MG WEEKLY PKT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor 80 mg combined with low-dose dexamethasone (20 mg) administered orally on day 1 and day 3 of each week in 4-week cycles
Study: 35379237
Drug: Selinexor 80
Normalized name: SELINEXOR 80MG WEEKLY PKT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor 80 mg combined with low-dose dexamethasone (20 mg)
Study: 35379611
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitors (TKIs) combined with anti-PD-1 antibody in arm A (obvious response to TKIs)
Study: 35379611
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitors (TKIs) in arm B (general response to TKIs)
Study: 35379611
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitors (TKIs) in arm C (poor response to TKIs)
Study: 35379630
Drug: Weekly text
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly text messages with three short questions assessing mood, worry, and pain (n=1851 subgroup)
Study: 35379737
Drug: camrelizumab plus
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: camrelizumab plus apatinib (3 cycles of neoadjuvant therapy including three doses for 21 days)
Study: 35379737
Drug: camrelizumab plus
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: camrelizumab plus apatinib (neoadjuvant therapy followed by surgery)
Study: 35379737
Drug: camrelizumab plus
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: camrelizumab plus apatinib (adjuvant therapy after surgery)
Study: 35379737
Drug: camrelizumab plus
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: camrelizumab plus apatinib (ctDNA status after adjuvant therapy)